GEN Exclusives

More »

GEN News Highlights

Back to Item »

Antisoma’s Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial

ASA404 failed as first-line treatment, and interim data on its potential as a second-line therapy is due later this year.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?